|
Evaluation of radiomic features on baseline CT scan to predict clinical benefit for pemetrexed based chemotherapy in metastatic lung adenocarcinoma. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim |
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech (Inst); Newlink Genetics (Inst); Pfizer (Inst) |
|
|
Research Funding - Merck Sharp & Dohme (Inst); Verastem (Inst) |
|
|
Consulting or Advisory Role - Anthem |
|
|
No Relationships to Disclose |
|
|
Honoraria - Foundation Medicine; Novartis; UpToDate |
Consulting or Advisory Role - Clovis Oncology |
Research Funding - Eisai (Inst); Genentech (Inst); OncoPlex Diagnostics (Inst); Trovagene (Inst) |